Target Audience
Infectious disease/clinical microbiology/infection prevention & control, and public health professionals from low-middle income countries (LMICs), dealing with the impact of the Covid-19 pandemic on healthcare systems.

Faculty Members
- Seif Al-Abri, Muscat, Oman
- Benedetta Allegranzi, Geneva, Switzerland
- Adrian Brink, Cape Town, South Africa
- Vincent Cheng, Hong Kong, China
- Mauricio J. Farfan, Santiago, Chile
- Alex Friedrich, Muenster, Germany
- Brian Godman, Glasgow, Scotland
- Guido Granata, Rome, Italy
- Lorenzo Guizzaro, Amsterdam, Netherlands
- Maria Eugenia Gutiérrez Pimentel, David, Panama
- Ivan Fan Ngai Hung, Hong Kong, China
- Florian Lasch, Amsterdam, Netherlands
- Shaheen Mehtar, Cape Town, South Africa
- Eskild Petersen, Aarhus, Denmark
- Nicola Petrosillo, Rome, Italy
- Pilar Retamar, Sevilla, Spain
- Camilla Rodrigues, Mumbai, India
- Maurizio Sanguinetti, Rome, Italy
- Herman Schramm, Nijmegen, Netherlands
- Nusrat Shafiq, Chandigarh, India
- Evelina Bacconelli, Verona, Italy
- Juan Pablo Torres, Santiago, Chile
- Ramasubramanian Venkataramanan, Chennai, India
- Margreet Vos, Rotterdam, Netherlands
- Kamini Walia, New Delhi, India
- Sean Wasserman, Cape Town, South Africa

Organiser
- ESCMID International Affairs Subcommittee – EIAS

Other Organisers
- EFAT, ESGNI, ESGAP, EUCIC, MJC IC UEMS

Course Coordinators
- Nicola Petrosillo, Rome, Italy
- Adrian Brink, Cape Town, South Africa

Contact
Contact Person (Scientific Programme)
Nicola Petrosillo
Foundation, University Hospital Campus Bio-medico
Via Alvaro del Portillo 200 – 00128 Rome
Italy
+39 06 25419955
n.petrosillo@policlinicocampus.it
nicola.petrosillo@escmid.org

Adrian J. Brink
Division of Medical Microbiology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Rondebosch, Cape Town, 7700
South Africa
+27 021 406 6083
adrian.brink@uct.ac.za

ESCMID Online
Education Course

COVID-19 collateral damage: impact on healthcare services in LMICs (Africa, Asia, South America)

Online
20 – 21 October 2022

Organisation

Registration Procedure
Register on the ESCMID website at www.escmid.org/education by 2 October 2022.

Registration Fee
EUR 150 for ESCMID members
EUR 200 for all others
For Young Scientist Members EUR 50
For LMICs EUR 20

Course Objective
The current and future impact of the COVID-19 pandemic on the healthcare systems is poorly understood. During the SARS-CoV-2 pandemic, numerous research studies and public health programs had been compromised substantially. All efforts and resources were directed to the fight against COVID-19. While this situation was equally important in European and North American countries, in LMICs from Asia, Africa, and South America, limited resources may have had a more substantial impact on health systems.

Notably, the redirection and allocation of health resources to the care of patients with COVID-19, resulted in a decrease in the prevention, diagnosis, treatment and follow-up of patients with infectious diseases such as HIV, TB, malaria, etc. Antenatal care and paediatric vaccination programs may also have been affected.

Moreover, infection prevention control (IPC) and antimicrobial stewardship programs (ASP) may have been affected due to the shortage of human resources and funding. In addition, the impact on antibiotic consumption in LMICs is mostly unknown. Several reports have highlighted the indiscriminate use of oral and intravenous antibiotics in LMICs, and the impact on antibiotic resistance bound to be substantial.

The aim of the course is to update the audience on the collateral health-care damages caused by the COVID-19 pandemic, concerning prevention and management of infectious diseases, clinical microbiology, IPC and ASPs in LMICs, and to assess the barriers, facilitators and strategies for the normal resumption of non-COVID-19 healthcare activities.
The COVID-19 pandemic has had both negative and positive impacts on infectious diseases of public health importance. Shifting public health resources to COVID-19 detection, control and prevention has negatively impacted, amongst others, on tuberculosis, malaria and sexually transmitted diseases control efforts. The audience will obtain knowledge to what extent control efforts have been affected in various parts of the world and what is required to negate the negative impact.

The COVID-19 pandemic has led the ongoing antimicrobial resistance (AMR) global crisis due to the increase in the use of antibiotics to treat COVID-19 patients and disruptions to infection prevention and control practices in overwhelmed health systems. The session will also focus on reviving surveillance of consumption and AMR, to enable strategized interventions.

The audience will learn how COVID-19 pandemic had fueled the original antimicrobial resistance (AMR) crisis. The session will be presented with strategies how to break down AMS and IPC silos, in light of increases in difficult-to-treat resistance.

The non-COVID-19 clinical trials at the time led the ongoing antimicrobial resistance (AMR) global crisis due to the increase in the use of antibiotics to treat COVID-19 patients and disruptions to infection prevention and control practices in overwhelmed health systems. The audience will learn how COVID-19 pandemic had fueled the original antimicrobial resistance (AMR) crisis. The session will be presented with strategies how to break down AMS and IPC silos, in light of increases in difficult-to-treat resistance.

**Course Programme**

**Session times are specified in Central European Summer Time (CET) – UTC+2**

**Thursday, 20 October 2022**

09:00 – 09:10 Reception & Opening

09:10 – 09:40 Welcome and overview of day two

10:00 – 10:30 Change in antibiotic consumption and resistance in India

10:30 – 10:45 Change in antibiotic consumption and resistance in India

10:40 – 11:00 Change in antibiotic consumption and resistance in India

11:00 – 11:30 Interactive session

The present and the future of the public health programmes and how to expedite “recovery”

11:30 – 11:45 Lunch break

**12:00 – 12:30**

**The non-COVID-19 clinical trials at the time of the pandemic**

Lorenzo Guzzaro (Netherlands)

Florian Lasch (Luxembourg)

12:30 – 12:45 Q&A

12:45 – 13:00 Interactive session

Research: how and when will it go back as before COVID-19?

13:00 – 14:00 Lunch break

**13:45 – 14:00**

Impact of COVID-19 on Infection Prevention & Control (IPC) interventions and initiatives

Moderators

Margaret Vos

Ramosubramanian Venkatasubramanian

Learning outcomes

The audience will learn not only of the impact in various regions of the world, but the current barriers, facilitators and strategies for the normal resumption of IPC and AMR surveillance.

14:00 – 14:30 Impact on IPC in Sub-Saharan Africa

Shaheen Mehtar (South Africa)

14:30 – 15:00 Impact on IPC in India

Camilla Rodrigues (South Africa)

15:00 – 15:30 Impact on IPC in China

Ivan Fan Ngai Hung (China)

15:30 – 16:00 Impact on IPC in South/Central America

Juan Pablo Torres (Chile)

16:00 – 16:30 Impact on IPC in North Africa-Middle East

Seif Al-Abri (Oman)

16:30 – 17:00 Impact of the pandemic on the surveillance of antimicrobial resistance (AMR) in the healthcare settings globally

Pilar Ronetame (Spain)

17:00 – 17:15 Q&A

**14:30 – 15:00**

Impact on IPC in Sub-Saharan Africa

**15:00 – 15:30**

Impact on IPC in China

**15:30 – 16:00**

Impact on IPC in South/Central America

**16:00 – 16:30**

Impact on IPC in North Africa-Middle East

**16:30 – 17:00**

Impact of the pandemic on the surveillance of antimicrobial resistance (AMR) in the healthcare settings globally

**17:00 – 17:15**

Q&A

**17:15 – 17:50**

Interactive session

COVID-19 vs IPC and AMR surveillance: what do we have to resume IPC and AMR surveillance and what strategies have worked or otherwise not

**17:50**

End of day

**Friday, 21 October 2022**

09:15 – 09:30 Welcome and overview of day two

10:00 – 10:30 Change in antibiotic consumption and resistance in India

10:30 – 10:45 Change in antibiotic consumption and resistance in India

10:40 – 11:00 Change in antibiotic consumption and resistance in India

11:00 – 11:30 Change in antibiotic consumption and resistance in South/Central America

11:30 – 11:45 Q&A

11:45 – 12:10 Interactive session

AMR in LMICs in the COVID-19 era: are we in too big a hole and how should we go about reducing consumption and minimize AMR spread?

12:10 – 13:10 Lunch break

**13:45 – 14:00**

Impact on IPC in Sub-Saharan Africa

**14:00 – 14:30**

Impact on IPC in India

**14:30 – 15:00**

Impact on IPC in China

**15:00 – 15:30**

Impact on IPC in South/Central America

**15:30 – 16:00**

Impact on IPC in North Africa-Middle East

**16:00 – 16:30**

Impact of the pandemic on the surveillance of antimicrobial resistance (AMR) in the healthcare settings globally

**16:30 – 17:00**

Impact of the pandemic on the surveillance of antimicrobial resistance (AMR) in the healthcare settings globally

**17:00 – 17:30**

Conclusions and closure of the course

17:30 – 18:30 Special session: AMR and IPC in the COVID-19 era: are we in too big a hole and how should we go about reducing consumption and minimize AMR spread?

**18:30 – 19:30**

End of day

**End of day**